Quick Facts

• Hypertension: Used to address elevated blood pressure levels.
• Angina Pectoris: May be utilized for the long-term management of chronic chest pain.
• Heart Failure: An available treatment option to support stable, symptomatic heart failure (NYHA Class II or III).

---

Beloc ZOK (metoprolol succinate extended-release) is a medication used to help manage specific cardiovascular conditions. Its primary therapeutic domains involve three core areas. It is utilized in the management of hypertension, which is a condition of elevated blood pressure. Achieving and maintaining appropriate blood pressure levels is part of comprehensive cardiovascular risk management.

The medication is also indicated for the long-term management of angina pectoris, a form of chest discomfort that occurs when the heart muscle does not receive enough oxygen. In this context, the drug is used to help reduce the frequency of angina attacks and may contribute to an improvement in exercise tolerance over time.

Finally, Beloc ZOK is an option for treating stable, symptomatic heart failure of certain origins (ischemic, hypertensive, or cardiomyopathic). When used in this population as an adjunct to other standard therapies, it is associated with a reduced risk of cardiovascular mortality and hospitalizations. Patients should consult their healthcare professional for a complete review of all approved indications and risks.

Regulatory References

1. NIH DailyMed guidance on metoprolol succinate extended-release

Beloc ZOK (metoprolol succinate extended-release) is contraindicated and must not be used in several patient groups, according to official regulatory labeling. These prohibitions are based on the risk of exacerbating severe pre-existing conditions.

Populations Excluded or Restricted from Use

Absolute Contraindications The medicine is prohibited for patients with severe bradycardia, second- or third-degree heart block, cardiogenic shock, decompensated heart failure requiring intravenous treatment, and known hypersensitivity to metoprolol or other beta-blockers. Use is also contraindicated in those with sick sinus syndrome unless a permanent pacemaker is installed.

Age and Conditional Restrictions Use is established for hypertension in pediatric patients aged 6 years and older, but it is not recommended for those under 6 years. Patients with impaired hepatic function require restricted use, necessitating the initiation of a lower dose due to the potential for increased metoprolol blood levels. Older adults should also be started on a low initial dose. Individuals with bronchospastic disease should generally avoid use, unless alternatives are unavailable. During pregnancy and lactation, use is conditional, with regulatory documentation stating newborns and breastfed infants must be monitored for signs of beta-blockade.

Beloc ZOK (metoprolol succinate) may interact with various other medicines, primarily through two mechanisms: increasing the risk of excessively slow heart rate or very low blood pressure (pharmacodynamic interaction) or increasing the amount of metoprolol in the bloodstream (pharmacokinetic interaction).

Potential Pharmacodynamic Interactions

Certain medicines can intensify the effects of Beloc ZOK on the heart rate and blood pressure, potentially leading to slow heart rate (bradycardia) or low blood pressure (hypotension). These include:

• Calcium Channel Blockers (Verapamil and Diltiazem type): Co-administration, especially intravenous, is generally avoided due to the risk of additive effects that severely depress heart function.
• Other Antiarrhythmic Agents (e.g., Quinidine, Amiodarone): Can increase the risk of an overly slow heart rate or heart conduction issues.
• Digitalis Glycosides and Clonidine: May also enhance the effect of slowing the heart rate.
• Catecholamine-Depleting Drugs (e.g., reserpine) and MAO Inhibitors: Can have an additive effect, increasing the risk of low blood pressure and bradycardia.

Pharmacokinetic Interactions (Increased Metoprolol Levels)

Metoprolol is primarily processed by the enzyme CYP2D6 in the liver. Inhibitors of this enzyme can reduce the breakdown of Beloc ZOK, leading to higher concentrations in the blood. Interacting medicines include:

• Certain Antidepressants (e.g., Fluoxetine, Paroxetine, Bupropion).
• Antihistamines (e.g., Diphenhydramine).
• Cimetidine (used for ulcers).
• Antimalarials (e.g., Hydroxychloroquine).

Other Notable Interactions

• Clonidine Withdrawal: If discontinuing clonidine, Beloc ZOK should be stopped first, several days before the gradual withdrawal of clonidine, to avoid a potential sudden, severe spike in blood pressure (rebound hypertension).
• Epinephrine (Adrenaline): Beloc ZOK may reduce the effectiveness of epinephrine used to treat severe allergic reactions (anaphylaxis). Higher doses of epinephrine may be required.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Certain NSAIDs may reduce the blood pressure-lowering effect of metoprolol.

Blocking Beta-1 Receptors to Reduce Heart Workload

This medication acts as an antagonist, binding selectively to the beta-1 adrenergic receptors located predominantly on cardiac muscle cells. This interaction competitively blocks the signaling of circulating hormones, specifically adrenaline and noradrenaline, from stimulating the heart. The resulting cascade leads to a direct decrease in the heart's rate (negative chronotropy) and a simultaneous lessening of the force of its contractions (negative inotropy), which results in a decrease in the oxygen required by the myocardium.

Modulation of the Renin-Angiotensin System

The drug's interaction with beta-1 receptors extends to the kidneys, influencing the Renin-Angiotensin System (RAS). By suppressing the release of the enzyme renin from the juxtaglomerular cells, the drug modifies this crucial regulatory pathway. This modification of the RAS cascade leads to the physiological consequence of lower systemic pressure and a decrease in systemic vascular resistance throughout the circulatory system.

How to Use Beloc ZOK

Beloc ZOK (metoprolol succinate extended-release) is an extended-release tablet intended for oral administration. A defining feature of this formulation is the once-daily dosing frequency, which allows for consistent blood plasma concentrations over a 24-hour period.

Administration and Handling

To maintain the modified-release characteristics of the tablet, the medication must be swallowed whole and must not be crushed or chewed. The tablet may be administered either with or without food.

Official Dosing Regimens

Starting and maintenance doses are tailored to the specific cardiovascular condition being managed. For hypertension and angina pectoris, typical starting doses range from 25 mg to 100 mg once daily, with the maintenance range extending up to 400 mg once daily, which is the maximum studied dose.

In the management of stable, symptomatic heart failure, a more gradual approach is required. Treatment is generally initiated at a low dose of 12.5 mg to 25 mg once daily. The dose is then carefully and incrementally increased, often by doubling every two weeks, to reach a target maintenance dose of 200 mg once daily as tolerated. Dosage adjustment for hypertension and angina is typically performed at weekly or longer intervals based on clinical response.

Special Populations and Discontinuation

Dose adjustment is generally not required for patients with chronic renal impairment. However, patients with significant hepatic impairment may require a lower starting dose. The treatment course for these conditions is typically long-term. If therapy needs to be stopped, the dosage must be gradually reduced over a period of one to two weeks; abrupt cessation is not advised.

Handling Instruction	Procedural Constraint
Tablet Integrity	Swallowed whole; do not crush or chew.
Dosing Schedule	Once daily; do not double dose if missed.
Discontinuation	Gradual reduction over 1–2 weeks.

Recent Clinical Evidence Overview

Clinical research on Beloc ZOK (metoprolol succinate extended-release) has primarily focused on its role in treating chronic heart failure (CHF) and hypertension (high blood pressure). Its extended-release formulation is designed to provide consistent beta-1-adrenergic receptor blockade over a 24-hour period, a key aspect evaluated in long-term studies.

---

Heart Failure Trials (MERIT-HF)

The largest and most influential trial, the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), evaluated the medication in patients with symptomatic CHF. Findings from this large-scale, randomized study indicated a significant reduction in the relative risk of all-cause mortality and the combined endpoint of mortality plus all-cause hospitalizations compared to placebo. These findings supported the inclusion of the extended-release formulation as a foundation of heart failure therapy, often used alongside other standard medications like ACE inhibitors and diuretics. Research has also included assessments of the drug's effect on left ventricular ejection fraction (LVEF), which is an important measure of cardiac function.

---

Safety and Tolerability Profiles

In major clinical trials, the medication was generally observed to be well-tolerated when compared to placebo, particularly when therapy was initiated at low doses and gradually increased. The most common adverse events reported in trials typically involved symptoms such as fatigue, dizziness, and headache. Studies have specifically examined the drug's safety and effectiveness across various patient groups, including elderly patients and those with diabetes mellitus and chronic heart failure.

Common questions about Beloc ZOK (FAQ)

Q: What are the approved indications for Beloc ZOK?

According to official regulatory documents, metoprolol succinate extended-release is approved for the treatment of several cardiovascular conditions. These indications include the treatment of hypertension (high blood pressure) and angina pectoris (chest pain). It is also indicated for use in stable, symptomatic heart failure (NYHA Class II or III).

Q: Does Beloc ZOK contain any dyes or common allergens?

The official product description lists several inactive ingredients used in the tablet, such as titanium dioxide, cellulose compounds, and polyethylene glycol. Regulatory information notes that the medication is contraindicated if a person has a known hypersensitivity or severe allergic reaction to metoprolol or any of these product components.

Q: What is the chemical name or formula for metoprolol succinate?

The active ingredient, metoprolol succinate, has a formal chemical description detailed in the regulatory labeling. The chemical name is (±) 1-(isopropylamino)- 3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (salt), which corresponds to the molecular formula C34H56N2O10.

Q: How long does it take for Beloc ZOK to start working after the first dose?

Official label information indicates that the maximum effect of any given dosage level for hypertension is generally seen after approximately one week of use. The extended-release (ZOK) formulation is designed to provide a controlled and gradual release of the drug over the full 24-hour period.

Q: What is the difference between Beloc ZOK and other metoprolol products?

Beloc ZOK contains metoprolol succinate, which is an extended-release formulation designed for once-daily administration. Immediate-release metoprolol products (such as metoprolol tartrate) have different dosing schedules than this extended-release formulation. Regulatory labeling notes that the succinate salt provides a controlled, predictable release profile throughout the day.

Q: Can Beloc ZOK be used in children?

Official regulatory documents confirm that metoprolol succinate extended-release tablets are approved for the treatment of hypertension in pediatric patients who are aged 6 years and older. However, the safety and effectiveness of the medication have not been studied or established for children who are under the age of 6.

Q: Is it okay to take Beloc ZOK with food?

According to official regulatory information, the drug may be administered with or without food. Taking the tablet with or without a meal does not significantly change the way the extended-release formulation is absorbed by the body.

Storage and Protection Requirements

Beloc ZOK (metoprolol succinate extended-release tablets) must be stored strictly according to regulatory guidelines to maintain its stability.

Requirement Type	Official Labeled Condition
Temperature	Store at Controlled Room Temperature (68^circF to 77^circF or 20^circC to 25^circC).
Environment	Must be protected from light, moisture, and excess heat.
Container	Keep the tablets in the original container, tightly closed, to ensure light and moisture resistance.
Safety	The medication must be kept out of the sight and reach of children.

Official Disposal Instructions

Regulatory authorities state that unused or expired Beloc ZOK should not be flushed down a toilet or poured down a sink. The required disposal method is a local drug take-back program. If a take-back program is unavailable, the product should be mixed with an undesirable substance (like dirt or coffee grounds), sealed in a container or bag, and discarded in the household trash.